• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

血清KL-6水平作为评估系统性硬化症患者肺纤维化的有用标志物。

Serum levels of KL-6 as a useful marker for evaluating pulmonary fibrosis in patients with systemic sclerosis.

作者信息

Yamane K, Ihn H, Kubo M, Yazawa N, Kikuchi K, Soma Y, Tamaki K

机构信息

Department of Dermatology, Faculty of Medicine, University of Tokyo, Japan.

出版信息

J Rheumatol. 2000 Apr;27(4):930-4.

PMID:10782818
Abstract

OBJECTIVE

KL-6 is a mucin-like glycoprotein that is strongly expressed on type II pneumocytes in the lung. Circulating KL-6 has been shown to be a sensitive marker of the disease activity of interstitial lung diseases. We determined the serum levels of KL-6 in patients with systemic sclerosis (SSc) and investigated whether these levels would serve as a useful marker of pulmonary fibrosis (PF) in patients with SSc.

METHODS

The serum KL-6 levels were determined using a specific ELISA in 91 patients with SSc, and in 38 healthy controls.

RESULTS

The serum levels of KL-6 were significantly higher in patients with SSc than in healthy controls (923+/-860 vs. 382+/-55 U/ml; p<0.0001). The serum KL-6 levels of the patients with diffuse cutaneous SSc (dSSc) tended to be higher than those with limited cutaneous SSc (ISSc) (1054+/-1000 vs. 800+/-694 U/ml), but there was no significant difference between these 2 groups. The serum KL-6 levels in the patients with PF were significantly elevated compared to those without PF (1283+/-1056 vs. 520+/-148 U/ml; p<0.0001). Moreover, DLCO and VC were also significantly decreased in the patients with elevated KL-6 levels compared to those with normal levels (62+/-22% vs. 72+/-17%, p<0.05; 87 +/-20% vs. 100+/-18%, p<0.01, respectively).

CONCLUSION

Serum KL-6 level may be a useful serum marker for evaluating pulmonary fibrosis in patients with SSc.

摘要

目的

KL-6是一种黏蛋白样糖蛋白,在肺Ⅱ型肺泡上皮细胞上强烈表达。循环中的KL-6已被证明是间质性肺疾病疾病活动的敏感标志物。我们测定了系统性硬化症(SSc)患者的血清KL-6水平,并研究这些水平是否可作为SSc患者肺纤维化(PF)的有用标志物。

方法

采用特异性酶联免疫吸附测定法(ELISA)测定91例SSc患者和38例健康对照者的血清KL-6水平。

结果

SSc患者的血清KL-6水平显著高于健康对照者(923±860 vs. 382±55 U/ml;p<0.0001)。弥漫性皮肤型SSc(dSSc)患者的血清KL-6水平倾向于高于局限性皮肤型SSc(lSSc)患者(1054±1000 vs. 800±694 U/ml),但两组之间无显著差异。与无PF的患者相比,PF患者的血清KL-6水平显著升高(1283±1056 vs. 520±148 U/ml;p<0.0001)。此外,与KL-6水平正常的患者相比,KL-6水平升高的患者的一氧化碳弥散量(DLCO)和肺活量(VC)也显著降低(分别为62±22% vs. 72±17%,p<0.05;87±20% vs. 100±18%,p<0.01)。

结论

血清KL-6水平可能是评估SSc患者肺纤维化的有用血清标志物。

相似文献

1
Serum levels of KL-6 as a useful marker for evaluating pulmonary fibrosis in patients with systemic sclerosis.血清KL-6水平作为评估系统性硬化症患者肺纤维化的有用标志物。
J Rheumatol. 2000 Apr;27(4):930-4.
2
Clinical significance of surfactant protein D as a serum marker for evaluating pulmonary fibrosis in patients with systemic sclerosis.表面活性蛋白D作为评估系统性硬化症患者肺纤维化血清标志物的临床意义。
Arthritis Rheum. 2001 Jun;44(6):1363-9. doi: 10.1002/1529-0131(200106)44:6<1363::AID-ART229>3.0.CO;2-5.
3
Comparative study of serum surfactant protein-D and KL-6 concentrations in patients with systemic sclerosis as markers for monitoring the activity of pulmonary fibrosis.系统性硬化症患者血清表面活性蛋白-D和KL-6浓度作为监测肺纤维化活动标志物的比较研究。
J Rheumatol. 2004 Jun;31(6):1112-20.
4
Serum pulmonary and activation-regulated chemokine/CCL18 levels in patients with systemic sclerosis: a sensitive indicator of active pulmonary fibrosis.系统性硬化症患者血清肺及活化调节趋化因子/CCL18水平:活动性肺纤维化的敏感指标
Arthritis Rheum. 2005 Sep;52(9):2889-96. doi: 10.1002/art.21257.
5
Elevated serum concentrations of polymorphonuclear neutrophilic leukocyte elastase in systemic sclerosis: association with pulmonary fibrosis.系统性硬化症患者血清中多形核中性粒细胞弹性蛋白酶浓度升高:与肺纤维化的关联
J Rheumatol. 2009 Jan;36(1):99-105. doi: 10.3899/jrheum.080269.
6
Serum level of KL-6 as a marker of interstitial lung disease in patients with juvenile systemic sclerosis.血清KL-6水平作为青少年系统性硬化症患者间质性肺疾病的标志物
J Rheumatol. 2004 Apr;31(4):795-800.
7
KL-6 as a novel serum marker for interstitial pneumonia associated with collagen diseases.KL-6作为胶原病相关间质性肺炎的一种新型血清标志物。
J Rheumatol. 2000 May;27(5):1164-70.
8
[Use of the the ED046 kit to analyze serum KL-6 in patients with pneumonitis].[使用ED046试剂盒分析肺炎患者血清中的KL-6]
Nihon Kyobu Shikkan Gakkai Zasshi. 1996 Jun;34(6):639-45.
9
Elevated serum concentrations of triggering receptor expressed on myeloid cells-1 in diffuse cutaneous systemic sclerosis: association with severity of pulmonary fibrosis.血清髓系细胞触发受体-1 水平升高与弥漫性皮肤系统性硬化症患者肺纤维化严重程度相关。
J Rheumatol. 2010 Apr;37(4):787-91. doi: 10.3899/jrheum.090664. Epub 2010 Feb 15.
10
[Clinical significance of serum KL-6 and SP-D for the diagnosis and treatment of interstitial lung disease in patients with diffuse connective tissue disorders].血清KL-6和SP-D在弥漫性结缔组织病患者间质性肺疾病诊断与治疗中的临床意义
Ryumachi. 2003 Feb;43(1):19-28.

引用本文的文献

1
PRDX-4: a novel biomarker similar to KL-6 for predicting the occurrence and progression of systemic sclerosis-ILD.PRDX-4:一种类似于KL-6的新型生物标志物,用于预测系统性硬化症相关间质性肺病的发生和进展。
Biomark Med. 2025 May;19(9):349-355. doi: 10.1080/17520363.2025.2485014. Epub 2025 Apr 1.
2
Risk factors for progression of pulmonary fibrosis: a single-centered, retrospective study.肺纤维化进展的危险因素:一项单中心回顾性研究。
Front Med (Lausanne). 2024 Feb 7;11:1335758. doi: 10.3389/fmed.2024.1335758. eCollection 2024.
3
KL-6 as a Biomarker of Interstitial Lung Disease Development in Patients with Sjögren Syndrome: A Retrospective Case-Control Study.
KL-6作为干燥综合征患者间质性肺疾病发展的生物标志物:一项回顾性病例对照研究
J Inflamm Res. 2022 Apr 8;15:2255-2262. doi: 10.2147/JIR.S352085. eCollection 2022.
4
Bronchoalveolar lavage and lung biopsy in connective tissue diseases, to do or not to do?结缔组织病中的支气管肺泡灌洗和肺活检,做还是不做?
Ther Adv Musculoskelet Dis. 2021 Dec 8;13:1759720X211059605. doi: 10.1177/1759720X211059605. eCollection 2021.
5
Serum IGFBP-2 in systemic sclerosis as a prognostic factor of lung dysfunction.系统性硬化症患者血清 IGFBP-2 作为肺功能障碍的预后因素。
Sci Rep. 2021 May 25;11(1):10882. doi: 10.1038/s41598-021-90333-0.
6
Comparative diagnostic efficacy of serum Krebs von den Lungen-6 and surfactant D for connective tissue disease-associated interstitial lung diseases: A meta-analysis.血清肺癌标志物-6和表面活性蛋白D对结缔组织病相关间质性肺疾病的诊断效能比较:一项荟萃分析。
Medicine (Baltimore). 2020 Apr;99(16):e19695. doi: 10.1097/MD.0000000000019695.
7
Serum levels of Krebs von den Lungen-6 as a promising marker for predicting occurrence and deterioration of systemic sclerosis-associated interstitial lung disease from a Chinese cohort.在中国队列中,血清克雷布斯-冯林根斯-6水平作为预测系统性硬化症相关间质性肺病发生和恶化的有前景的标志物。
Int J Rheum Dis. 2019 Jan;22(1):108-115. doi: 10.1111/1756-185X.13452. Epub 2018 Dec 28.
8
Sequential changes of serum KL-6 predict the progression of interstitial lung disease.血清KL-6的连续变化可预测间质性肺疾病的进展。
J Thorac Dis. 2018 Aug;10(8):4705-4714. doi: 10.21037/jtd.2018.07.76.
9
Elevated serum Krebs von den Lungen-6 in systemic sclerosis: a marker of lung fibrosis and severity of the disease.血清 Krebs von den Lungen-6 水平升高与系统性硬化症:肺纤维化和疾病严重程度的标志物。
Rheumatol Int. 2018 May;38(5):813-819. doi: 10.1007/s00296-018-3987-3. Epub 2018 Feb 17.
10
Serum KL-6 and surfactant protein-D as monitoring and predictive markers of interstitial lung disease in patients with systemic sclerosis and mixed connective tissue disease.血清KL-6和表面活性蛋白-D作为系统性硬化症和混合性结缔组织病患者间质性肺疾病的监测和预测标志物。
J Thorac Dis. 2017 Feb;9(2):362-371. doi: 10.21037/jtd.2017.02.48.